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ABSTRACT  Heparan  sulfate was isolated from the cell surface, cell pellet, and culture medium 
of exponentially  growing as well as postconfluent  bovine aortic smooth muscle cells (SMCs). 
After chromatography  on  DEAE-Sephadex and Sepharose 4B, the various mucopolysaccha- 
rides were  examined  for  their ability  to cause growth  inhibition  in  a SMC  bioassay. The 
heparan sulfate isolated from  the surface of postconfluent  SMCs possessed approximately 
eight times the antiproliferative  potency  per cell of the  heparan sulfate obtained  from  the 
surface of  exponentially  growing  SMCs. Heparan sulfate isolated from  other  fractions  of 
exponentially  growing or postconfluent  SMCs possesses little growth  inhibitory activity. The 
difference  in the antiproliferative  activities of heparan sulfate obtained  from  the surface of 
SMCs in the two growth  states could not be attributed  to the synthesis of a greater mass of 
mucopolysaccharide by postconfluent SMCs. Indeed, heparan sulfate isolated from the surface 
of the postconfluent SMCs exhibits a specific antiproliferative  activity which is 13-fold greater 
than mucopolysaccharide obtained from the surface of exponentially growing SMCs and more 
than 40-fold  greater than commercially available heparin. In addition,  exponentially growing 
SMCs did not exhibit an enhanced ability to degrade the complex carbohydrate. Furthermore, 
other investigations indicate that the small amount  of growth  inhibitory activity  intrinsic to 
heparan sulfate isolated from the surface of exponentially  growing SMCs is due to residual, 
biologically  active, mucopolysaccharide produced  by the primary postconfluent  SMCs from 
which the exponentially growing SMCs were derived. These studies suggest that bovine aortic 
SMCs are  capable of controlling  their own  growth  by the  synthesis of a specific form  of 
heparan sulfate with antiproliferative  potency. 
Most connective tissues contain glycosaminoglycans as major 
components of their extracellular matrix. These high molec- 
ular weight, negatively charged sulfated mucopolysaccharides 
have been implicated in determining certain general overall 
properties of tissues such as hydration, elasticity, and perme- 
ability (1). It has also been suggested that glycosaminoglycans 
that are known to be associated with the surface of the cell 
could be involved in basic cellular functions, such as adhesion 
and motility (2,  3). However, little is known about whether 
specific structural  elements on  the glycosaminoglycans are 
responsible for the biologic properties of these components. 
Several investigators have demonstrated that the mucopol- 
ysaccharide, heparin, must satisfy unique structure-function 
relationships to interact with its protein co-factor, antithrom- 
bin, to alter allosterically the conformation of this protease 
inhibitor, and thereby accelerate neutralization of  coagulation 
system enzymes (4). Our laboratory has recently shown that 
anticoagulantly active heparan sulfate molecules are present 
on the surface of endothelial cells and are, in part, responsible 
for maintaining the nonthrombogenic properties of the vessel 
wall (5, 6). These findings suggest that various types of cells 
may be able to synthesize heparan sulfate moieties of unique 
structure that could regulate other biologic systems via highly 
specific interactions.  The available data indicate that there 
may be different structural requirements for the various func- 
tions of these mucopolysaccharides. 
Guyton et al. (7) have provided evidence that the admin- 
istration of either anticoagulantly active or anticoagulantly 
inactive heparin to rats after endothelial injury suppresses the 
subsequent  in  vivo  proliferation  of smooth  muscle  cells 
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(11) have also shown that SMC growth under in vitro condi- 
tions can be inhibited by both forms of heparin, as well as by 
a  heparin-like product from endothelial cells.  Here we de- 
scribe the isolation and growth inhibitory potencies of hepa- 
ran sulfates obtained from bovine aortic SMCs at two stages 
of cell growth. We present evidence that postconfluent as well 
as exponentially growing SMCs  synthesize heparan  sulfate 
proteoglycans, but that only postconfluent SMCs produce a 
cell  surface-associated heparan  sulfate with potent antipro- 
liferative activity. These results suggest a mechanism by which 
SMCs may play a part in the regulation of their own growth 
via the production of this specific form of heparan sulfate. 
MATERIALS  AND  METHODS 
Enzymes:  Flavobacterium  heparinase was purified from Flavobacterium 
heparinum, provided by Dr. R. Langer (Massachusetts Institute of  Technology, 
Cambridge, MA) as previously described (5). The final preparation  of Flavo- 
bacterium  heparinase  was homogeneous  as judged  by  nonequilibrium  pH 
gradient electrophoresis (pH 3.5-10) using 4% acrylamide gels containing 8 M 
urea. The heparin cleaving activity of the purified bacterial enzyme was 3,650 
U/mg as determined  by Azure A hyperchromicity.  An analysis of the Flavo- 
bacterium heparinase revealed no significant proteolytic activity as quantitated 
by  hydrolysis of t2~I-labeled alpha-casein.  Chondroitinase  activity  was  not 
observed in the purified enzyme preparation  as measured  by degradation  of 
chondroitin  4-S and 6-S or dermatan sulfate. 
Platelet heparitinase, an endoglycosidase, was isolated from human platelets 
as previously described (12). The final preparation was physically homogeneous 
as judged  by  disk  gel  electrophoresis  at  acidic pH  as  well as gel  filtration 
chromatography  and  exhibited a specific activity  of 11  U/rag. This enzyme 
hydrolyzes glucuronsyl-glucosamine linkages within heparin or heparan sulfate 
and has no effect on other glycosaminoglycans or proteins (12). 
Papain  pronase  (protease,  type  XIV),  and  chondroitin  ABC  lyase were 
obtained  from Sigma Chemical Co. (St. Louis, MO). Chondroitin  ABC lyase 
completely degraded chondroitin  4- and 6-sulfates (Sigma Chemical Co.) and 
had no activity against commerically available heparin (Diosynth, Inc., Chicago, 
IL) or National  Institutes of Health standard  heparan  sulfate, Trypsin-EDTA 
solution was obtained from Flow Laboratories (McLean, VA). 
All other chemicals were obtained from Fisher Scientific Co. (Medford, MA) 
unless otherwise noted. 
Cell Culture:  SMCs were grown  from  explants  of bovine  aortas  as 
previously described (13). After  removing  the  endothelium,  small pieces of 
media were carefully stripped  from the  vessel wall. Fragments  of the  media 
with average dimensions of 5 × 5 mm were placed with their lumen side up in 
100-mm-diameter tissue culture dishes (Costar, Cambridge,  MA). Each dish 
contained 5 ml of Dulbecco's modification of Eagle's minimal essential medium 
(Flow Laboratories), bovine calf serum (Flow Laboratories) at a final concen- 
tration  of 10%, 100 U/ml of penicillin (E. R. Squibb & Sons, Inc., Princeton, 
N  J), and  100 ~g/ml of streptomycin  sulfate (Eli Lilly, Co., Indianapolis,  IN) 
(10% CS-DME). The explants were incubated in the 10% CS-DME for 7 d in 
a humidified 5% CO2 atmosphere. Thereafter, the medium was changed every 
3-4 d. After 4-5 wk of growth, the resultant  cells were examined by electron 
microscopy and appeared identical to vascular SMCs described by others (14). 
In particular, numerous myofilament bundles were noted in the cytoplasm and 
vesicles were observed near surface membranes. 
Radiolabeling  and  Isolation  of  SMC  Glycosaminogly- 
cans:  Primary cultures of bovine SMCs 4-5 wk after explant, were treated 
with 0.05% trypsin-0.02%  EDTA solution  for 5 min at 37"C, and were then 
subcultured  in  10% CS-DME at a cell density of 0.25 x  l04 cells/cm 2. When 
cells had  reached the  desired growth  stage, 24  h  or  l0 d  later, the  culture 
medium  was removed and replaced with fresh  10%  CS-DME containing  50 
~Ci/ml  of Na23~SO4 (-200 mCi/mmol) (New England Nuclear, Boston, MA) 
and incubation was continued  for 48 h. At the end oftbe radiolabeling period, 
the culture medium was aspirated and saved, the cells were washed five times 
with  phosphate-buffered  saline (NaCl,  0.137 M,  KCI 0.0027 M,  Na2HPO4, 
0.0081  M,  KH2PO4, 0.0015 M,  pH  7.5) (PBS), and  cell surface-associated 
glycosaminoglycans were  released by  treatment  with  0.05% trypsin-0.02% 
' Abbreviations used in this paper:  10%  CS-DME, Dulbecco's modi- 
fication of Eagle's minimal essential medium, bovine calf serum at a 
final concentration of 10%,  100  U/ml of penicillin, and  100  ug/ml 
of streptomycin sulfate; SMC, smooth muscle cell. 
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EDTA  solution  for  20  min  at  37°C. The  cell density  at  the  end  of the 
radiolabeling period was ~7.5 x  104 cells/cm 2. The cell pellet was harvested by 
centrifugation at 100 g for 5 min at 4"C. The supernatant,  which contained the 
cell surface associated glycosaminoglycans, was boiled for  10  rain  and then 
saved for further  processing. The cell pellet was resuspended  in  1-2  ml  of 
distilled,  deionized  water  and  the  cells were  homogenized  with  a  Dounce 
homogenizer. Pronase,  1 mg/ml, was added to the homogenate and digestion 
was carried out at  37"C for 24  h. Papain,  1 mg/ml, was then admixed  and 
incubation continued  for an additional 24 h. The cell digest was centrifuged at 
4,000 g for  10 min at 4°C to remove debris, and the supernatant  was saved. 
Culture  medium  from  radiolabeled  exponentially  growing or postconfluent 
SMC cultures was concentrated  by lyophilization and chromatographed  at a 
flow rate of 8 ml/h on a column of  Sephadex GS0 ( 1.2 cmx 45 cm) (Pharmacia 
Fine Chemicals, Piscataway, N  J) equilibrated in 0.1 M NAG1, 0.01 M Tris-HCl, 
pH 7.5, to remove unincorporated  radioactivity. The macromolecular material 
was  pooled  and  lyophilized.  Cell surface,  cell pellet, and  culture  medium 
samples were extensively dialyzed against 0.4 M NaCI, 0.01 M Tris-HCl, pH 
7.5 (DEAE equilibration  buffer) in preparation  for DEAE-Sephadex chroma- 
tography. 
Isolation of Radiolabeled SMC Heparan Sulfate:  Cellsurface, 
cell pellet, and medium fractions from exponentially growing or postconfiuent 
SMC cultures were chromatographed  on a column of DEAE-Sephadex A50 
(1.9 cm  x  185  cm)  (Pharmacia  Fine  Chemicals).  After  washing  with  two 
column volumes of equilibration  buffer, glycosaminoglycans were eluted with 
a linear salt gradient that  used a mixing chamber containing  1,000 ml of 0.4 
M NaCI in 0.01 M Tris-HCI, pH 7.5, and a reservoir containing  1,000 ml of 
2.0 M NaCI in 0.01 M Tris-HCl, pH 7.5. The flow rate of the column was 25 
ml/h and 7-ml fractions were collected. Fractions were monitored  for 35S by 
counting an aliquot representing ~ 1% of the fraction volume. All scintillation 
counting employed Ultrafluor scintillation fluid (National Diagnostics, Somer- 
ville, N  J). Peak fractions were pooled and concentrated  by rotary evaporation. 
The heparan  sulfate pool obtained  by DEAE-Sephadex chromatography  was 
filtered at a flow rate of 5 ml/h on a column of Sepharose 4B (1.5 cm ×  110 
era) (Pharmacia  Fine Chemicals) equilibrated with 0.1  M NAG1, 0.01 M Tris- 
HCI, pH 7.5. Fractions of 2 ml were collected and radioactivity determined  as 
described above. The pooled glycosaminoglycans were digested with Pronase, 
1 mg/ml, in 0.01 M calcium acetate, 0,01 M Tris-HCl, pH 8.0, for 24  h at 
37"C, and rechromatographed on the same column. Peak fractions were pooled, 
concentrated  by rotary  evaporation  and dialyzed extensively against PBS for 
enzymatic analysis or bioassay, or against distilled, deionized water for gluco- 
samine analysis. 
Quantitation  of Mucopolysaccharides:  SMC heparan sulfate or 
porcine mucosal standard  heparin (Diosynth, Inc., Chicago IL, lot number LP 
041681) was hydrolyzed  in  6  M  HC1  for 3 h  in  vacuo  at  100*C (15). The 
glucosamine  content  of the  hydrolysates  was  determined  by  ion  exchange 
chromatography  with  a  Durrum  D-500  amino  acid  analyzer.  The  values 
obtained were multiplied by appropriate conversion factors to provide estimates 
of the  amount of heparan  sulfate  or heparin  within  a  given fraction.  The 
conversion factors were derived by examining known amounts (dry weight) of 
the National Institutes of Health standard  mucopolysaccharides. 
Identification of SMC Glycosaminoglycans:  Radiolabeled gly- 
cosaminoglycans isolated by ion-exchange chromatography  and gel filtration 
were identified  by  specific enzymatic  degradation.  To this  end,  35S-labeled 
mucopolysaccharides were incubated with 30 U of Flavobacterium  heparinase 
or 50 ng of platelet heparitinase or 0.1  U of chondroitin  ABC lyase at 37"C for 
24 h and were boiled for 10 min. Samples were obtained both before as well as 
immediately after treatment  with the above enzymes, and were then analyzed 
by high performance liquid chromatography  at a flow rate of 1 ml/min using 
a Waters  Liquid Chromatography  System (Waters Associates, Milford, MA) 
and a Toya Soda TSK G2000  SW column (Toya Soda Mfg,, Tokyo, Japan) 
(HPLC/G2000  SW) equilibrated  with either  1 M NaG1 or  1 M ammonium 
acetate,  pH 6.5. Fractions  were collected at 0.4-rain  intervals and  peaks of 
radioactivity were located as described above. Degradation of mucopolysaccha- 
rides was ascertained by comparing the levels of complex carbohydrate present 
in the excluded volume of the column (polysaccharides) visa vis those located 
in the included volume of the column (oligosaccharides). 
Bioassay of the Growth  Inhibitory Activity of SMC C/ycos- 
aminoglycans:  First passage SMCs in  10% CS-DME were seeded at 6 x 
10  ~ cells per  16-ram well in cluster-24 plates (Costar, Cambridge,  MA) and 
allowed to attach for 24 h at 37"C in humidified 5% CO2. On day 1, the SMCs 
were arrested in Go (G~) by removing  the growth  medium,  washing the  cell 
layers twice with PBS, and adding  1 ml of 0. 1% platelet-poor human plasma- 
DME to each well. Cells were incubated at 37"C in humidified 5% CO2 for an 
additional  72 h. On day 4, the cells were released from Go block and exposed 
to the antiproliferative action of mucopolysaccharides. This was accomplished 
by  removing  the  growth  arrest  medium,  and  adding  either  10%  CS-DME (control cultures) or 10% CS-DME with heparin at levels that ranged from 0.01 
to  10 #g/ml (heparin standard curve) or  10% CS-DME with heparan sulfate 
samples at given concentrations of mucopolysaccharide. The SMCs were in- 
cubated at 37"C in humidified 5% CO2 for an additional 7 d. At no time during 
this incubation did microscopic examination reveal evidence of cells detaching 
from  the  surface  of the  wells.  The  cell  numbers on  days  4  and  11  were 
determined in duplicate by trypsinizing the SMCs and counting the dislodged 
cells in a Coulter counter (Coulter Electronics, Inc., Hialeah, FL, model ZF). 
To ascertain that the procedure had not lysed the SMCs and to ensure that all 
cells were removed from the cluster-24 plates, we routinely checked trypsinized 
multiwells by direct microscopic examination. The net growth of SMCs in the 
control cultures was obtained by subtracting the starting cell  number (day 4) 
from the cell number on day I I. The net growth of SMCs in various concen- 
trations of heparin  standards or heparan sulfate samples were computed in 
similar fashion. The degree of inhibition for a given level of mucopolysaccharide 
was calculated from the following relationship: % inhibition =  I -  (net growth 
in culture medium containing mucopolysaccharide/net growth in control cul- 
ture medium) x  100. The antiproliferative potencies of heparan sulfate fractions 
were computed by comparing the percent inhibition of cell growth obtained at 
a given level of the sample with that induced by the heparin standards. For this 
purpose, we have assumed that  one  inhibitory  unit  of biological  activity  is 
equivalent to the percent inhibition of cell growth produced by l /~g/ml of the 
heparin standard. The specific  antiproliferative potency of a given fraction of 
heparan sulfate is calculated by dividing the biological  activity of the sample 
by the mass of the sample as determined by glucosamine analysis. By definition, 
the specific antiproliferative potency of the heparin standard is set at a value of 
1.0. 
The standard  error of the  mean in  percent  for the  measurement of the 
inhibitory activity of heparan sulfate or the specific antiproliferative potency of 
heparan sulfate within a single experiment or between different experiments in 
which the same source of mucopolysaccharide, SMCs, and serum was used is 
-7%. The standard error of the mean for the measurement of the inhibitory 
activity of heparan sulfate or specific antiproliferative potency ofheparan sulfate 
among experiments in which different sources of mucopolysaccharide, SMCs, 
and serum were used is -6%. 
RESULTS 
Isolation of SMC Heparan Sulfate 
Primary cultures of bovine SMCs were treated with 0.05% 
trypsin-0.02% EDTA solution for 5 min at 37"C, and were 
then split at a  1:10 ratio into culture dishes with  10%  CS- 
DME.  We initially examined glycosaminoglycans from two 
stages of SMC growth. The first stage was chosen  1 d  after 
plating, when the SMCs had doubled approximately 0.5 time 
(exponentially growing SMCs). The second stage was selected 
10 d after plating, when the SMCs had been confluent for ~5 
d (postconfluent SMCs). The SMCs, at either stage of growth, 
were incubated for 48 h in fresh medium containing Na235SO4. 
The medium was saved, the cells were washed with PBS, and 
cell  surface glycosaminogiycans were released by treatment 
with  0.05%  trypsin-0.02%  EDTA  solution  for  20  min  at 
37"C.  After this procedure,  ~95  percent of the SMCs were 
viable as evidenced by trypan blue exclusion. The cell pellet 
was  harvested by centrifugation,  homogenized,  and  exten- 
sively proteolyzed with pronase and papain. Medium samples 
were concentrated and desalted by chromatography on Seph- 
adex G50 (see Materials and Methods for additional experi- 
mental details). Cell surface, cell pellet, and culture medium 
samples were then dialyzed against 0.4 M NaC1, 0.01  M Tris- 
HC1, pH 7.5. 
The radiolabeled glycosaminoglycans from the cell surface, 
cell pellet, and culture medium of exponentially growing and 
postconfluent  SMCs  were  isolated  by chromatography on 
DEAE-Sephadex  A50  and  Sepharose  4B.  DEAE-Sephadex 
chromatography resolved the  35S-labeled material  obtained 
from the surface of exponentially growing and postconfluent 
SMCs into two peaks (Fig.  1). Peak I eluted at a salt concen- 
tration of 0.65 to 0.80 M NaC1, and was identified as heparan 
sulfate  by  its  sensitivity  to  digestion  with  Flavobacterium 
heparinase as well  as its resistance to digestion  with  chon- 
droitin ABC lyase. Peak II eluted at a  salt concentration of 
0.88 to 1.08 M NaC1 and was identified as chondroitin sulfate 
by its sensitivity to digestion with chondroitin ABC lyase as 
well as its resistance to digestion with Flavobacterium hepa- 
rinase. The exponentially growing and postconfluent SMCs 
exhibited approximately equivalent amounts of cell surface 
heparan sulfate (38.7  __. 9.3% vs. 47.2 _  4.9%) and chondroi- 
tin sulfate (55.1  __.  10.2%  vs.  46.4  __.  1.5%) based upon the 
relative levels of 35S counts within the two peaks. Peaks I and 
II were  tested  with  respect  to  their  ability  to  inhibit  the 
proliferation of smooth muscle cells in a biological assay as 
outlined in Materials and Methods. The assay results indicate 
that the antiproliferative potency of peak I material is more 
than 500-fold greater per 105 cpm than that of peak II mate- 
rial. The inhibitory activity of  peak I was completely destroyed 
by digestion  with  Flavobacterium  heparinase  and  was  un- 
changed following treatment with chondroitin ABC lyase. 
Glycosaminoglycans from cell  pellet or medium of expo- 
nentially growing and  postconfluent SMCs were also chro- 
matographed on DEAE-Sephadex (not shown).  Two major 
peaks were observed which eluted at ionic strengths similar 
to those of peaks I and II and were degraded by Flavobacter- 
ium heparinase and chondroitin sulfate in a fashion identical 
to peaks I and II. However, the exponentially growing and 
postconfluent  SMCs  exhibited  only  small  amounts  of cell 
pellet or medium  heparan  sulfate (10.3  __.  2.1%  vs.  8.3  __. 
1.3%) as compared to chondroitin  sulfate (85.7  __.  5.4%  vs. 
87.5  ___ 3.8%) based upon the relative 35S counts within the 
two peaks.  Peaks I  and  II from cell surface, cell  pellet,  or 
2,000 
1,5OO 
IpO0 
5OO 
W 
tl  •  I 
i 
I  1  1  1  1 
70  90  IIO  130  150 
FRACTION NUMBER 
I.IO 
I.OO 
0,90 
z 
0.80 
0.70 
0.60 
0.50 
FIGURE  I  DEAE-Sephadex  chromatography  of  radiolabeled  gly- 
cosaminoglycans from the surface of postconfluent and exponen- 
tially growing SMCs. The 35S-labeled glycosaminoglycans obtained 
from the surface of postconfluent (- -  -) or exponentially growing 
(  ) SMC by treatment with trypsin-EDTA were chromatographed 
a  column  of  DEAE-Sephadex A50.  Concentrations of  NaCl were 
determined  based on  conductance  measurements. See Materials 
and Methods for additional experimental detail. 
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nm. 
The heparan sulfate-containing fractions from the cell sur- 
face, cell pellet, and culture medium of exponentially growing 
as well as postconfluent SMCs were individually chromato- 
graphed on Sepharose 4B as described in Materials and Meth- 
ods. Heparan sulfate from the surface of postconfluent SMCs 
separated into two peaks (Fig.  2A).  Proteolytic digestion of 
peak I with pronase and subsequent rechromatography of the 
material on Sepharose 4B revealed a heparan sulfate species 
with an elution position identical to that of peak II (Fig. 2A). 
Similar treatment of peak II resulted in no detectable change 
in the elution position of this component. Given the above 
results,  heparan sulfate from peaks I and II were pooled for 
further processing.  Heparan sulfate from the surface of expo- 
nentially growing cells displayed only one peak after chro- 
matography on Sepharose 4B and the position of the peak 
did not change upon digestion with pronase (Fig. 2B). The 
elution position of this latter peak coincided with that of the 
protease treated heparan sulfate from the surface of postcon- 
fluent SMCs (Fig. 2A, peak II). The approximate molecular 
weights  of  the  two  cell  surface  mucopolysaccharide  are 
35,000-40,000, as determined by the elution position of gly- 
cosaminoglycan standards of similar charge density. Sepha- 
rose  4B  chromatography of heparan  sulfate  from  the  cell 
pellet or culture medium of  exponentially growing or postcon- 
fluent SMCs revealed a  single  major peak with an average 
molecular weight of 35,000-40,000 (data not shown). Proteo- 
lytic digestion of heparan sulfate from cell pellet, or culture 
medium of exponentially growing and postconfluent SMCs 
did not change the elution position of these components. 
Growth Inhibitory Activity of SMC 
Heparan Sulfate 
The antiproliferative activity of heparan  sulfate  isolated 
from  the  cell  surface,  cell  pellet,  and  culture  medium  of 
exponentially growing and postconfluent SMCs was quanti- 
rated with a SMC growth inhibition assay. The data show that 
heparan sulfate obtained from the surface of a given number 
of postconfluent SMCs possesses  approximately eight times 
the amount of antiproliferative activity of the heparan sulfate 
present on the surface of the same number of exponentially 
growing  SMCs  (Table  I).  The  data  also  indicate  that  the 
heparan sulfates from the cell pellet,  and culture medium of 
similar numbers of exponentially growing and postconfluent 
SMCs contain only minimal amounts of this biologic activity 
(Table I). It should be noted that chondroitin sulfate derived 
from the cell surface, cell pellet, or culture medium of expo- 
nentially growing or postconfluent SMCs has no growth in- 
hibitory activity when assayed at levels l0 to 100 times higher 
than that used with heparan sulfate (data not shown). 
The chemical masses of heparan sulfate obtained from the 
cell surface, cell pellet, and culture medium of exponentially 
growing and postconfluent SMCs were determined by direct 
measurement of glucosamine. It is apparent from these data 
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FIGURE 2  Sepharose 4B chromatography of heparan sulfate from the surface of postconfluent and exponentially growing SMCs. 
The heparan  sulfate  pool obtained  by  DEAE-Sephadex chromatography was gel filtered  on a Sepharose 4B column.  Elution 
profiles are provided for heparan  sulfate  isolated  from the surface of postconfluent SMCs (A) and exponentially growing SMCs 
(B) before (  ) and immediately after (- -  -) protease digestion. Proteolytic digestion was accomplished by incubation of the 
heparan  sulfate with pronase.  Chondroitin sulfate  molecular weight standards were generously provided by Dr.  L.  Rosenberg 
(Montefiore Hospital, Bronx, NY). Additional experimental details are provided in Materials and Methods. 
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1.5 to 3.0 times the mass of heparan sulfate found on the cell 
surface, cell pellet, or culture medium of the same number of 
postconfluent SMCs cells (Table I). The specific antiprolifer- 
ative potency of heparan sulfate derived from the cell surface, 
cell pellet,  or culture medium of exponentially growing and 
postconfluent SMCs was calculated by dividing the biological 
activity of a given sample by the chemical mass of that same 
sample. The specific antiproliferative activity of the heparin 
standard is set at  1.0. The results show that heparan sulfate 
isolated from the surface of postconfluent SMCs possesses the 
highest specific antiproliferative activity of any fraction ex- 
amined, with a  potency approximately 13-fold greater than 
that of heparan sulfate obtained from the similarly designated 
compartment of exponentially growing cells and more than 
40-fold greater than that of the heparin standard (Table I). 
Indeed, this growth inhibitory cell surface heparan sulfate can 
function at the nanogram level in suppressing the proliferation 
of SMCs (Fig.  3). The specific antiproliferative activities of 
heparan sulfate derived from the cell pellet, and medium of 
exponentially growing and postconfluent SMCs were consid- 
erably lower with potencies closely approximating that of the 
heparin standard (Table I). 
The results cited above were obtained with an assay that 
employs SMCs that have been growth arrested by exposure 
to low concentrations of platelet-poor plasma before admix- 
ture with heparan sulfate samples or heparin standards and 
10% CS-DME. However, exponentially growing SMCs,  cul- 
tured in 5% CS-DME, without previous growth arrest are also 
sensitive to the action of heparin and heparan sulfate.  Data 
virtually identical to those outlined above were obtained when 
exponentially growing SMCs were employed in the growth 
inhibition  assay.  Indeed, the  extent of growth suppression 
induced by heparin or heparan sulfate in the exponentially 
growing cell  assay  is  approximately equal  to  70%  of that 
observed in the growth arrested cell assay (data not shown). 
TABLE  I 
Chemical Mass and Antiproliferative Activities of Heparin Sulfate 
Isolated from Exponentially Growing and Postconfluent SMCs 
Specific 
Antipro-  antipro- 
liferative  Heparin  liferative 
Fraction growth stage  activity  sulfate  activity 
Inhibitory 
units/lO ° 
cells 
2.97 
#g/lO 6 cells 
Cell surface (exponentially grow-  0.818  3.63 
ing) 
Cell surface (postconfluent)  22.35  0.499  44.82 
Cell pellet (exponentially  growing)  1.27  0.640  1.98 
Cell pellet (postconfluent)  1.21  0.464  2.61 
Culture  medium  (exponentially  1.80  0.680  2.63 
growing) 
Culture medium (postconfluent)  0.63  0.236  2.65 
The chemical  mass of heparin sulfate obtained from  the cell  surface, cell 
pellet, and medium of exponentially growing as well as postconfluent SMCs 
was  determined  by  glucosamine  assay.  The  antiproliferative activity  was 
calculated by comparing the amount of growth inhibition produced by each 
sample to that produced by known amounts of the heparin standard. Under 
these conditions, 1 #g of heparin per milliliter produced a 30-40% inhibition 
of growth  relative to control cells which  underwent four to five doublings 
during the experiment. Cell numbers in control wells typically reached 0.8- 
1.0 x  10  s cells per centimeter squared. One inhibitory unit is equivalent to 
the amount of inhibition caused by 1 #g of heparin per milliliter. The specific 
antiproliferative activity of a given heparin sulfate is computed  by dividing 
the growth inhibitory activity of the sample by its chemical mass. The specific 
antiproliferative activity of heparin  is equal to  1.  Additional  experimental 
detail is provided in Materials and Methods. 
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FIGURE 3  The  dose  response  curves  for  heparin  and  heparan 
sulfate in the SMC growth inhibition assay. The growth inhibitory 
activities of the heparin standard and heparan sulfate isolated from 
the surface of postconfluent SMCs were determined as outlined in 
Materials  and  Methods.  Each point in  the  heparin curve  (---) 
represents the average of at least 10 determinations in experiments 
using the same heparin standard. Each point in the heparan sulfate 
curve (  ...... ) represents the average of at least four determinations 
in experiments using three different preparations of heparan sulfate 
isolated from the surface of postconfluent SMCs. 
Characterization of Heparan Sulfate Isolated from 
the Surface of Postconfluent SMCs 
Heparan sulfate obtained from the surface of postconfluent 
SMCs was digested with platelet heparitinase or Flavobacter- 
ium  heparinase and  the  resultant  species  were assayed for 
their antiproliferative potency. Platelet heparitinase, an en- 
doglycosidase,  cleaves heparan sulfate at glucuronsylglucosa- 
mine  linkages  producing  fragments  with  a  wide  range  of 
molecular sizes (12). Flavobacterium  heparinase, an exogly- 
cosidase,  scissions  heparan sulfate at sulfated glucosaminyl- 
iduronic acid linkages  generating disaccharides and tetrasac- 
charides (16).  Neither enzyme displays any activity against 
other glycosaminoglycans or proteins. 
Platelet heparitinase cleaved the cell surface heparan sulfate 
of 35,000  to  40,000  mol  wt  (Fig.  4A)  into  fragments  of 
molecular weight that range from 35,000 to 1,300 (Fig. 4B). 
The undigested heparan sulfate and the resultant fragments 
were tested for antiproliferative activity in the growth inhibi- 
tion assay. Undigested heparan sulfate was designated pool I 
(35,000  to  40,000  mol  wt)  (Fig.  4A);  the  heparan  sulfate 
fragments were arbitrarily divided into  pool  II  (35,000  to 
13,000 tool wt),  pool III (12,000 to 7,500 mol wt),  pool IV 
(6,500 to 4,500 mol wt), and pool V (2,600 to 1,300 mol wt) 
(Fig. 4B). Undigested heparan sulfate and fragment pools II 
through IV exhibited approximately 25 inhibitory units per 
l05 cpm,  whereas pool V  possessed  essentially no antipro- 
liferative potency. Flavobacterium  heparinase scissioned  the 
cell surface glycosaminoglycan into tetrasaccharides and di- 
saccharides of molecular weight  1,300 and 650, respectively 
(Fig.  4C).  Flavobacterium  heparinase-digested heparan sul- 
fate was divided into pools VI (35,000 to 2,600 mol wt), pool 
VII (2,600 to 900 mol wt) and pool VIII (<900 mol wt) (Fig. 
4 C).  The degraded heparan sulfate exhibited no inhibitory 
activity before column chromatography and pools VI and 
VII, as well as VIII, possessed no antiproliferative potency. 
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FIGURE  4  The sensitivity of heparan sulfate  isolated from the sur- 
face of postconfluent SMCs to enzymatic cleavage. Heparan sulfate 
obtained from the surface  of postconfluent SMCs was incubated 
for 24  h  at  37°C  with  PBS  buffer control  (A),  50  ng of  platelet 
heparitinase (B), or 30  U of Flavobacterium heparinase  (C). After 
incubation, the samples were analyzed by HPLC/G2000  SW.  Frac- 
tion pools, as shown by brackets,  were concentrated by lyophili- 
zation, dissolved in PBS, and assayed to determine residual growth 
inhibitory activity. Molecular size markers indicate the elution po- 
sitions of heparin fragment standards of 22, 12, 8, 4, and 2 saccha- 
ride  residues.  These  components were  prepared as  previously 
described (10). See Materials and Methods for additional experi- 
mental detail. 
An Evaluation of the Ability of Exponentially 
Growing SMCs to Degrade Heparan Sulfate with 
Growth Inhibitory Activity 
The difference in the specific antiproliferative activities of 
heparan  sulfate isolated  from  the  surface of exponentially 
growing and postconfluent SMC might be due to the ability 
of exponentially growing cells  to  preferentially degrade  or 
partially desulfate the mucopolysaccharide with antiprolifer- 
ative  potency.  To  test  this  hypothesis,  we  incubated  ass- 
labeled  heparan  sulfate  from  the  surface of postconfluent 
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SMCs for 24 h at 370C in 10% CS-DME with or without first 
passage exponentially growing SMCs at a density of 104 cells 
per cm  2. At the end of this time, the radiolabeled material 
within the culture medium was  analyzed by HPLC/G2000 
SW. As shown in Fig. 5, heparan sulfate incubated for 24 h 
in  10% CS-DME exhibited a minor reduction in molecular 
size which is probably caused by the action of small amounts 
of platelet heparitinase normally found within calf serum (9). 
However, no further change in peak profile was detected when 
heparan sulfate was incubated in the presence of  exponentially 
growing SMCs. These results suggest that extensive scissioning 
of heparan sulfate by exponentially growing SMCs does not 
take place. Furthermore, no peak of radioactivity eluting in 
the included volume of the column was detected that would 
correspond to free 35S. These findings strongly indicate that 
exponentially growing SMCs would not be able to reduce the 
biologic activity of heparan sulfate by desulfating the muco- 
polysaccharide. 
The Source of the Small Amounts of 
Antiproliferative Heparan Sulfate Isolated from 
the Surface of Exponentially Growing SMCs 
We have standardly obtained exponentially growing SMCs 
by exposing primary postconfluent SMCs to a 0.05 % trypsin- 
0.02%  EDTA solution for 5 min before subculturing.  The 
subsequent  harvesting  of  surface  glycosaminoglycans  is 
achieved by a 20-min treatment of the SMCs with the same 
type solution of trypsin-EDTA. Therefore, it is possible  that 
the small amounts of heparan sulfate with antiproliferative 
activity isolated from the  surface of exponentially growing 
SMCs represent residual mucopolysaccharide present on the 
initially seeded postconfluent SMCs, which was not removed 
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FIGURE  5  The  ability of  exponentially growing SMCs to  cleave 
heparan sulfate  isolated from the surface of postconfluent SMCs. 
First passage SMCs were plated in 10% CS-DME at 2.0 x  104 cells/ 
ml in cluster-24 plates, 1 ml/well. Wells were also prepared without 
ceils.  After  24  h  of  incubation at  37°C  in  5%  CO2, 3SS-labeled 
heparan sulfate  isolated  from the surface  of postconfluent SMCs 
were added  to  wells with  (--)  or  without  (  )  SMCs, and 
incubation was continued for an additional 24 h. At the end of the 
incubation period, the culture medium was removed, filtered, and 
0.5 ml was analyzed by HPLC/G2000  SW. Controls consisted of an 
equal volume of culture medium from wells with or without SMCs 
to which 35S-labeled  heparan sulfate was added immediately before 
injection. The elution position of the control peak is indicated by 
an arrow. Additional experimental detail is  provided in  Materials 
and Methods. by the 5-min trypsinization employed before plating. To test 
this hypothesis, we measured the antiproliferative activity of 
cell  surface heparan  sulfate per  10  6 cells  from the time of 
plating (day 0) to the stage  of postconfluence examined in 
this communication (day 12). Table II provides a comparison 
of the observed antiproliferative activity of cell surface hepa- 
ran sulfate per 10  6 cells during different stages of  growth, with 
theoretical values calculated by assuming that exponentially 
growing  SMCs  possess  the  initially  measured  amounts  of 
growth  inhibitory  mucopolysaccharide  found  on  primary 
postconfluent SMCs but do not synthesize these biologically 
active complex carbohydrates. In this case, the residual anti- 
proliferative activity of heparan sulfate per 106 cells obtained 
from  the  surface  of SMCs  should  be  diluted  as  a  linear 
function of the growth of the transferred primary postcon- 
fluent SMCs.  The data in Table II suggest that most of the 
residual antiproliferative heparan sulfate present on the sur- 
face of exponentially growing and confluent SMCs can be 
accounted  for  by  this  mechanism.  However,  the  level  of 
growth inhibitory heparan  sulfate found on the  surface of 
postconfluent SMCs is  38 times what was  expected. These 
results indicate that postconfluent SMCs have the ability to 
synthesize the antiproliferative heparan sulfate and place this 
component on their surface while the exponentially growing 
and confluent SMCs have little, if  any, of  this capacity. Indeed, 
a comparison of observed postconfluent and confluent anti- 
proliferative activities suggests a difference of  several hundred- 
fold in this parameter. Preliminary data indicate that synthesis 
of the antiproliferative heparan sulfate begins 4 to 5 d after 
SMCs reach confluence (data not shown). 
DISCUSSION 
The SMCs found within the medial region of the arterial wall 
are normally present in a relatively quiescent growth state ( 17, 
18). However, experimental desquamation of the overlying 
endothelium permits platelets to adhere to the denuded sur- 
face with  subsequent  release of mitogens such  as  platelet- 
derived growth  factor 07-20).  Macrophages  may  also  be 
present within this region of the vasculature and may liberate 
TABLE  II 
Theoretical and Observed Activities  of Heparin  Sulfate Isolated 
from the Surface of SMC at Different Stages of Growth 
No. of cells/  Theoretical  Observed 
Time in culture  cm 2  activity  activity 
Inhibitor/  Inhibitor/ 
Days  x  10 4  unitsllO 6 cells  unitsllO 6 cells 
0  0.254  17.17 
3  (exponentially  2.71  1.61  2.97 
growing) 
5  (confluent)  6.34  0.69  0.14 
12 (postconfluent)  7.53  0.58  22.35 
Primary cultures of SMCs were labeled with 35S and exposed to trypsin-EDTA 
solution for 5 min as described in Materials and Methods. This first trypsin- 
cell suspension was removed from the culture dishes, centrifuged, and the 
cells were replaced in the culture dishes. Fresh trypsin-EDTA solution was 
added and  incubation  was continued  for an  additional  15  rain.  The  3SS- 
labeled surface-associated glycosaminoglycans removed by this  5-20  min 
exposure to  trypsin  were  purified  by  column  chromatography  to  obtain 
heparin  sulfate. Surface-associated heparin  sulfate was also purified  from 
SMC cultures at 3,  5, and  12 d after initiation of the cultures. The antipro- 
liferative potencies of the various samples of heparin sulfate were determined 
with  the SMC growth  inhibition  assay and the activities are expressed per 
106 cells.  The theoretical values for the antiproliferative activity of exponen- 
tially growing, confluent, and postconfluent cells are calculated as described 
in the text. See Materials and Methods for experimental details. 
such  mitogens  as  macrophage-derived growth  factor (21). 
These components can bind to specific receptors on the SMC 
membrane and induce these cellular elements to migrate to 
the luminal surface of the blood vessel as well as stimulate 
them to undergo an exuberant proliferative response (22-24). 
The resultant myointimal lesion bears a striking resemblance 
to the early atherosclerotic plaque (17,  18). It also appears 
likely that endothelial cells themselves may be able to synthe- 
size  and  release  mitogens  that  can  induce  migration  and 
proliferation of SMCs (25). Hence abnormalities in the gen- 
eration  of these  mitogens  by  endothelial  cells  as  well  as 
platelets and macrophages might also result in the develop- 
ment of the myointimal plaque described above. 
Several laboratories have provided evidence that  natural 
components may exist within the vessel wall that could oppose 
the  action  of the  above  mitogens  and  hence  prevent the 
development of smooth  muscle  proliferation.  Clowes  and 
Karnovsky (26)  showed  in  a  rat  model  that  exogenously 
administered  commercial  heparin  markedly  suppressed 
myointimal proliferation following injury to the endothelium. 
These investigators initially believed that the antiproliferative 
action of heparin might be due to the ability of the mucopol- 
ysaccharide to accelerate antithrombin-dependent inhibition 
of thrombin.  However, a  collaborative study conducted by 
this group and our laboratory revealed that anticoagulant as 
well as non-anticoagulant heparin, prepared by affinity-frac- 
tionation on antithrombin-Sepharose, are equally effective in 
suppressing SMC proliferation under in vivo conditions (7). 
Hoover et al. (1 l) were then able to demonstrate with cultured 
rat SMCs that both forms of heparin could inhibit the growth 
of these cellular elements under in vitro conditions. These 
studies indicated that the structural determinants on the hep- 
arin molecule that are responsible for antiproliferative activity 
are distinct from those which are required for anticoagulant 
potency. 
Given the above findings, we wondered whether endothelial 
cells  might  produce  heparin-like  molecules that  could  be 
released  by  specific enzymes and  that  might  regulate the 
growth of SMCs.  With this hypothesis in mind, Castellot et 
al.  (8) were able to show that conditioned culture medium 
from bovine aortic endothelial cells  inhibits the growth of 
aortic SMCs and that serum is required for the release of the 
antiproliferative activity. The molecular species  responsible 
for growth inhibition was initially identified as a heparin-like 
component since its antiproliferative activity could be com- 
pletely destroyed when incubated with purified Flavobacter- 
ium heparinase. Thereafter, Castellot et at.  (9) and Oosta et 
al.  (12) provided compelling evidence that the serum com- 
ponent that released the  heparin-like species  with  antipro- 
liferative activity from the surface of bovine endothelial cells 
was a platelet endoglycosidase that scissions  occasional glu- 
curonsyl-glucosamine bonds.  This  enzyme  has  also  been 
found within the lysosomes of different cell types including 
SMCs (Fritze, L., and R.  D. Rosenberg, unpublished obser- 
vation). 
However, we have recently isolated a heparan sulfate from 
the medial region of the bovine aortic wall and have shown 
that this mucopolysaccharide is able to inhibit the growth of 
SMCs (Reilly, C. and R. D. Rosenberg, manuscript in prep- 
aration). Since SMCs are the predominant cell type within 
this segment of the vascular tissue,  we thought it likely that 
these cells might also synthesize heparin-like molecules that 
could regulate their own growth potential. We investigated 
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surface,  cell  pellet,  and  culture  medium  of exponentially 
growing and postconfluent SMCs and determining their an- 
tiproliferative potencies. 
To accomplish this purpose, we incubated primary cultures 
of exponentially growing as well as postconfluent SMCs with 
Na235SO4 and obtained the radiolabeled glycosaminoglycans 
from the cell surface, cell pellet,  as well as culture medium. 
These molecular species  were freed of protein by extensive 
proteolytic digestion and the  resultant mucopolysaccharide 
chains were isolated by DEAE-Sephadex and Sepharose 4B 
chromatography. The latter chromatographic techniques sug- 
gest that the average size and average charge density of either 
heparan sulfate or chondroitin sulfate are virtually identical, 
independent of cellular origin and growth stage. The bioassay 
of these components demonstrated that heparan sulfate from 
the cell surface, cell pellet, and culture medium of exponen- 
tially growing,  as well as postconfluent SMCs,  exhibits anti- 
proliferative activity, whereas the similarly designated frac- 
tions of chondroitin sulfate possess no such biologic potency. 
Therefore, the anionic charge of the heparan sulfate cannot 
be the sole  reason for the growth inhibitory potency of this 
component,  since  the  DEAE-Sephadex  chromatographic 
analyses clearly show that chondroitin sulfate has a  higher 
average charge density than heparan sulfate. Indeed, the above 
findings indicate that certain specific  structural elements of 
heparan sulfate, such as glycosidic bond configuration, sulfate 
position, or iduronic acid residues,  are required for the ob- 
served antiproliferative effect  (10). The data in Table I indicate 
that heparan sulfate isolated from the surface of  postconfluent 
SMCs exhibits about eight times the antiproliferative potency 
of the corresponding material obtained from the surface of 
exponentially growing SMCs.  Heparan sulfate isolated from 
the cell pellet or culture medium of SMCs in either growth 
state possesses only minimal amounts of  the growth inhibitory 
activity. 
To prove that heparan sulfate itself was responsible for the 
antiproliferative phenomenon observed above, we exposed 
the postconfluent SMC mucopolysaccharide  to either purified 
Flavobacterium heparinase or platelet endoglycosidase, sepa- 
rated the resultant species by HPLC/G2000 SW, and assayed 
these components for growth inhibitory activity. On the one 
hand, our results indicated that degradation of the heparan 
sulfate to tetrasaccharides and disaccharides completely abol- 
ished antiproliferative potency. On the other hand, our data 
showed that cleavage of the heparan sulfate into larger frag- 
ments with  molecular weights  that  ranged from 20,000  to 
1,300 had little effect on the growth inhibitory activity per 
105 35S counts until a molecular weight of about 4,000 (do- 
decasaccharide) was  attained.  Our  demonstration  that  the 
antiproliferative potency of the  heparan  sulfate comigrates 
with the 35S counts of large fragments of  the mucopolysaccha- 
ride and that the growth inhibitory activity of the heparan 
sulfate can be eliminated by degradation of the mucopolysac- 
charide to tetrasaccharides and disaccharides strongly sup- 
ports our contention that this glycosaminoglycan is responsi- 
ble for the suppression of SMC proliferation. 
The chemical masses  of the various fractions of heparan 
sulfate were also determined by hexosamine analyses and the 
specific antiproliferative activity of these glycosaminoglycans 
were calculated. The data showed that exponentially growing 
SMCs synthesize about 1.5 to 3.0 times the amount ofheparan 
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sulfate found in the corresponding fractions of postconfluent 
SMCs.  Thus, the large  amounts of antiproliferative activity 
present on the surface of postconfluent SMCs are not simply 
due to the augmented production of this glycosaminoglycan. 
Indeed,  the  heparan  sulfate  isolated  from  the  surface  of 
postconfluent SMCs had a specific inhibitory activity which 
is  13 times that of the similarly designated mucopolysaccha- 
ride obtained from exponentially growing SMCs. This highly 
active beparan  sulfate is able to  inhibit dramatically SMC 
proliferation when added at a level as low as 20 ng/ml and 
hence its potency is more than 40 times greater than that of 
commercial heparin in suppressing the growth of these cells. 
We thought it possible  that the reduced specific  antipro- 
liferative activity of heparan sulfate obtained from the surface 
of exponentially growing SMCs might be due to the degra- 
dation of the biologically active component by these cellular 
elements. To examine this hypothesis, we incubated radiola- 
beled heparan sulfate from the surface of postconfluent SMCs 
with exponentially growing SMCs for 24 h  and showed by 
HPLC/G2000 SW chromatography that minimal cleavage or 
desulfation had taken place. 
Thus  our  data  indicate  that  postconfluent  SMCs  are 
uniquely able to synthesize a heparan sulfate with remarkably 
potent antiproliferative activity and place these components 
on their cell  surface.  This highly active heparan  sulfate is 
likely to differ structurally to only a very minor extent when 
compared to  mucopolysaccharides isolated  from exponen- 
tially growing cells  since both types of glycosaminoglycans 
appear to have similar average molecular sizes and average 
charge densities. 
Given  that  the  surface  of exponentially growing  SMCs 
possess heparan sulfate with minimal growth inhibitory activ- 
ity, we wondered whether the levels of this biologically potent 
mucopolysaccharide could  represent  residual  highly  active 
glycosaminoglycan generated by the  primary postconfluent 
SMCs used to seed our cultures. To test this hypothesis, we 
harvested the surface glycosaminoglycans present on SMCs 
from the  time of seeding to the  period of postconfluence, 
isolated  heparan  sulfate  by  column  chromatography, and 
ascertained the antiproliferative activity of the mucopolysac- 
charide per  10  6 cells. Our results indicate that exponentially 
growing SMCs retain small amounts of residual highly active 
heparan  sulfate from the  surface of primary postconfluent 
SMCs but can produce little of the biologically active com- 
ponent.  Indeed,  we  would  suggest  that  the  postconfluent 
SMCs and SMCs at other stages of growth probably differ by 
as much as several hundred-fold in their ability to synthesize 
heparan  sulfate with  growth  inhibitory potency and  place 
these components on their surface. It is also of  interest to note 
that the production of the biologically potent glycosamino- 
glycan appears to be abruptly induced at ~4 d after confluence 
is attained (data not shown). The molecular signals needed to 
accomplish this end are unknown  but could be similar to 
those required to express specific  receptors on cell surfaces 
immediately after the cessation of growth (27, 28). 
At the present time, it is difficult to explain completely the 
relative absence of the heparan sulfate with growth inhibitory 
activity  from  the  culture  medium  and  cell  pellet  of the 
postconfluent SMCs. These findings may be due to the differ- 
ential placement of this component on the surface of the cells 
with an associated reduction in the sensitivity of this glycos- 
aminoglycan to platelet endoglycosidase in the serum. With respect  to  the  intracellular  levels  of heparan  sulfate  with 
antiproliferative activity, our observations are consistent with 
the  presence  of a  large  pool  of minimally  active  heparan 
sulfate within the postconfluent SMCs and/or an accelerated 
destruction  of mucopolysaccharide  with  growth  inhibitory 
potency within the SMCs.  In this regard,  other investigators 
have observed that secreted and cell surface heparan sulfate 
are handled  as separate metabolic pools in other cell types 
(29). 
On the basis of the above observations, we would propose 
a simple model for the possible role of heparin-like compo- 
nents and endoglycosidase in the regulation of SMC growth 
within the vessel wall. In the normal artery, endothelial cells, 
macrophages, and/or platelets serve as sources for mitogenic 
factors necessary for the growth of medial SMCs.  However, 
SMCs also generate a  specific type  of heparan  sulfate with 
antiproliferative activity that is positioned at the surface of 
the  cell.  The  endoglycosidase that  can  liberate  the  growth 
inhibitory  mucopolysaccharide  is  also  available  within  the 
vessel wall. Under normal circumstances, the net effect of the 
mitogenic factors and the synthesis/release of the above hep- 
aran  sulfate  permits  a  small  amount  of  SMC  growth  to 
compensate for the death of these cellular elements (<0. 1% 
per day). 
During damage to the endothelium, platelets and macro- 
phages would appear at the site  of injury and  release high 
concentrations of growth factors. The SMCs might be able to 
respond  to  these  pathologic alterations by  augmenting the 
synthesis/release of the heparan sulfate with antiproliferative 
activity in a fashion identical to that noted when these cellular 
elements reach a  postconfluent stage of cell growth. In this 
situation, the net balance between the elevated concentrations 
of mitogenic factors and the increased levels of free heparan 
sulfate with growth inhibitory activity would ultimately de- 
termine whether SMCs migrate to the luminal surface of the 
blood vessel wall and mount a proliferative response. Thus, 
this specific form of heparan sulfate would be positioned to 
act as a negative control element during the regulation of cell 
proliferation in a similar manner to that postulated for certain 
proteins isolated from the surface of 3T3 cells and endothelial 
cells (30,  31).  It should be possible to test the above model 
once the structure of this unique heparan sulfate has been 
elucidated and the biosynthetic steps required to generate the 
mucopolysaccharide have been defined. 
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